Melleins are 3,4-dihydroisocoumarins mainly produced by fungi, but also by plants, insects and bacteria. These specialized metabolites play important roles in the life cycles of the producers and they are involved in many biochemical and ecological processes. This review outlines the isolation and chemical and biological characterizations of natural-occurring melleins from the first report of (R)-mellein in 1933 to the most recent advances in their characterization in 2019. In addition, the pathways that could be involved in mellein biosynthesis are discussed, along with the enzymes and genes involved.

Jasmonates are signaling compounds that regulate plant responses to stress. Jasmonic acid (JA) is the direct precursor of the bioactive plant hormone JA-isoleucine (JA-Ile), the ligand of the CORONATINE INSENSITIVE 1–jasmonate ZIM-domain (COI1–JAZ) co-receptor complex. JA, its methyl ester, and three furanonyl esters were recently isolated from the grapevine pathogen Lasiodiplodia mediterranea. The JA ester lasiojasmonate A (LasA) is the first reported naturally occurring JA-furanone, and its mode of action has not yet been elucidated. Here, we show that LasA activates many JA-regulated responses in planta, including protein degradation, gene expression, and physiological processes. These in vivo effects require LasA conversion into JA, formation of JA-Ile, and its recognition by the plant JA-Ile perception complex. These findings suggest a mode of action of the natural fungal LasA as an inactive JA pool that can be transformed into the bioactive JA-Ile form. We propose that fungal production of JA derivates such as LasA occurs at late infection stages to induce plant JA responses such as cell death, and can facilitate fungal infection.

Background: Alzheimer's disease (AD) is one of the most common causes of dementia in old people. Neuronal deficits such as loss of memory, language and problem-solving are severely compromised in affected patients. The molecular features of AD are Aβ deposits in plaques or in oligomeric structures and neurofibrillary tau tangles in brain. However, the challenge is that Aβ is only one piece of the puzzle, and recent findings continue to support the hypothesis that their presence is not sufficient to predict decline along the AD outcome. In this regard, metabolomic-based techniques are acquiring a growing interest for either the early diagnosis of diseases or the therapy monitoring. Mass spectrometry is one the most common analytical platforms used for detection, quantification, and characterization of metabolic biomarkers. In the past years, both targeted and untargeted strategies have been applied to identify possible interesting compounds. Aim of review: The overall goal of this review is to guide the reader through the most recent studies in which LC–MS-based metabolomics has been proposed as a powerful tool for the identification of new diagnostic biomarkers in AD. To this aim, herein studies spanning the period 2009–2020 have been reported. Advantages and disadvantages of targeted vs untargeted metabolomic approaches have been outlined and critically discussed.